Dr. Christopher D. Jakubowski

Balazs Halmos, MD received his medical degree summa cum laude from Semmelweis University in Budapest, Hungary. He completed an internal medicine residency program at St. Dr. Halmos is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Small Cell Lung Cancer (SCLC), and Tissue Biopsy. Dr. Halmos is currently accepting new patients.

Deepa Manwani is a Hematologist and an Oncologist practicing medicine in Bronx, New York. Dr. Manwani is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemolytic Anemia, Hemoglobinopathy, and Splenectomy.

Caterina Minniti is a Hematologist and an Oncologist practicing medicine in Bronx, New York. Dr. Minniti is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, and Hemolytic Anemia.

Benjamin A. Gartrell, MD, is Director, Genitourinary Malignancy Program at Montefiore and an Assistant Professor of Oncology and Urology at our Albert Einstein College of Medicine. Since joining the Montefiore team in 2012, his expertise has been in treating genitourinary malignancies including prostate cancer, bladder cancer, renal cell cancer, and testicular cancer. He is also very active in translating science findings in collaboration with research colleagues at Einstein. In 2000, Dr. Gartrell received his Bachelor of Arts in Chemistry at the College of Wooster in Ohio. Following this, he attended the Northwestern University?s Feinberg School of Medicine, in Chicago, Illinois, where he received his Doctor of Medicine in 2005. His postgraduate training began in 2005 with an internship and residency in Internal Medicine at Case Western Reserve University, which he completed in 2008. He then completed a fellowship in Hematology/Oncology at Mount Sinai School of Medicine in 2012 and became Chief Fellow from 2010-2011. With a vast range of research interests, Dr. Gartrell focuses on translational research evaluating the significance of a novel immune checkpoint molecule in bladder cancer, evaluating the role of the autonomic nervous system in?prostate cancer, toxicities associated with anticancer therapies, and the impact of bone metastasis on patients with prostate cancer. His work has been published in a number of peer-reviewed journals, including the Journal of Clinical Oncology, Urologic Oncology, and European Urology. Dr. Gartrell also participates in community outreach to promote Prostate Cancer Awareness. Dr. Gartrell is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Renal Cell Carcinoma (RCC), WT1-Related Wilms Tumor Syndromes, Nephrectomy, and Prostatectomy. Dr. Gartrell is currently accepting new patients.

James McKiernan, MD, is the John K. Lattimer Professor of Urology and CEO of ColumbiaDoctors. He is also Senior Vice Dean for Clinical Affairs for Columbia University Vagelos College of Physicians and Surgeons. Dr. McKiernan graduated from Johns Hopkins University with a BA in biology and received his MD from Columbia University College of Physicians and Surgeons. He completed his training in urology and general surgery at NewYork-Presbyterian Hospital, followed by a urologic surgical oncology fellowship at Memorial Sloan-Kettering Cancer Center. Dr. McKiernan's clinical practice is focused on urologic oncology and particularly on surgical therapy in high-risk patients with bladder and kidney cancers. Dr. McKiernan evaluates and treats over 1,000 patients with bladder cancer every year. His research, funded by NIH and biotechnology industry grants, focuses on developing novel therapeutics for bladder cancer treatment as well as comparative effectiveness research in urologic oncology. In the management of kidney and bladder cancer, he has special expertise in organ preservation and reconstructive surgery to maximize quality of life. Dr. McKiernan's research has been published in Cancer, Cancer Research, the Journal of Clinical Oncology, JAMA Oncology, Journal of Urology, Urologic Oncology, and Urology. He has authored and co-authored more than 220 scientific articles and book chapters on urologic cancer and related issues.For the past 10 years, he has directed a research team at Columbia University Medical Center investigating quality outcomes and effectiveness in urologic cancer surgery. He has served as the Vice Chairman for the AJCC TNM Staging Task Force, Co-Chair of the AUA Guidelines Panel on non-muscle invasive bladder cancer, as well as on the American Board of Urology and Society of Urologic Oncology Examination Committees. In addition, Dr. McKiernan is the principal investigator of the NIH-funded clinical trials program of experimental therapeutics in bladder cancer at Columbia University/NYPH, which is investigating new agents for bladder preservation in patients whose cancer has recurred after standard therapy. In collaboration with researchers at Columbia's Herbert Irving Comprehensive Cancer Center, his team continues to develop new therapeutic strategies for managing bladder cancer. Dr. Mckiernan is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Muscle Invasive Bladder Cancer, Urothelial Cancer, Cystectomy, and Nephrectomy. Dr. Mckiernan is board certified in Urology. Dr. Mckiernan is currently accepting new patients.

Yvonne Saenger is a Hematologist and an Oncologist practicing medicine in Bronx, New York. Dr. Saenger is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Melanoma, Cholangiocarcinoma (Bile Duct Cancer), Familial Pancreatic Cancer, and Pancreatic Cancer.